Comprehensive Eye Care & Vision Correction in Incheon · Multilingual International Concierge
23+ Years Clinical Experience
en-US
Ophthalmology Guide
ICL vs LASIK: High Myopia or Thin Corneas?
ICL vs LASIK for high myopia or thin corneas: how additive, reversible ICL compares with permanent LASIK, plus candidacy and trade-offs.
Schedule a ConsultationICL vs LASIK: Which Fits High Myopia or Thin Corneas?
Medically reviewed by Dr. Young Min Kim, Korean Board-Certified Ophthalmologist, Global Ubal Eye Center
Two Different Philosophies: Additive vs Subtractive
The single most useful way to understand ICL and LASIK is to think of them as opposites in approach.
What the US-FDA Approvals Actually Say
Regulatory status is a useful anchor because it reflects review of a specific device for a specific purpose.
Why Corneal Thickness Changes the Conversation
Corneal thickness is often the deciding factor between these two procedures, so it deserves a close look.
High Myopia: Where the Difference Is Most Visible
High myopia is the second situation where ICL and LASIK diverge sharply.
Trade-Offs and Risks: An Honest Comparison
Every procedure carries trade-offs, and being clear-eyed about them is essential.
Recovery and Daily Life
People often ask how the two procedures compare after surgery. Both LASIK and ICL are designed as outpatient refractive procedures, and both typically involve a period of healing, prescribed eye drops, and scheduled follow-up visits so the surgeon can confirm the eye is settling as expected.
How the Decision Is Actually Made
The choice between ICL and LASIK is not made from an article or a checklist. It is made after a comprehensive eye examination.
The Bottom Line
- ICL is additive and reversible; LASIK is subtractive and permanent. ICL adds a phakic lens inside the eye while keeping your natural lens, whereas LASIK removes corneal tissue to reshape the surface.
- Corneal thickness and degree of myopia are pivotal. Thin corneas or very high myopia may rule out LASIK, and these are precisely the situations where ICL is often discussed.
- US-FDA status is specific. The EVO/EVO+ Visian ICL is US-FDA-approved (March 2022) for myopia in adults ages 21–45; LASIK uses US-FDA-approved excimer lasers. Approval is not a guarantee of any particular result.
- Both carry distinct risks. ICL involves intraocular considerations such as vaulting, endothelial cell monitoring, and pressure; LASIK involves flap creation and permanent corneal reshaping.
- The decision belongs to the exam. Candidacy is determined by a comprehensive evaluation with your eye doctor, not by prescription number alone, and no procedure can promise a specific level of vision.
Frequently Asked Questions
**Is ICL better than LASIK for high myopia?**Neither is universally "better." ICL is frequently considered for high myopia because it adds a lens inside the eye rather than removing corneal tissue, which is a limiting factor for large LASIK corrections. The right choice depends on your specific measurements and is decided at a comprehensive exam.
More Articles
Continue reading our ophthalmology guides and vision care insights.
SMILE vs LASIK: Recovery Benchmarks for Vision Correction Care
South Korea has solidified its position as a global epicenter for ophthalmology, with the domestic LASIK and refractive surgery market projected to reach **USD 167.37 million by 2035**, growing at a steady CAGR of 8.54%.
Learn More
Prevalence of Myopia in Korea: The Value of Dream Lens Therapy
The prevalence of myopia among young people in South Korea has reached critical levels, often described as a "myopia epidemic." According to recent data from the **Korean National Health and Nutrition Examination Survey (KNHANES)**, the prevalence of myopia...
Learn More
Multidisciplinary Care: The Future of Korean Pediatric Eye Clinics
The landscape of pediatric eye care in South Korea is shifting rapidly. With nearly **21.9% of Korean children** estimated to be affected by various visual disorders according to nationwide health screenings, the demand for specialized intervention has never...
Learn More